American College of Rheumatology
HGSI's Phase III Benlysta Details Boost Confidence in Second Trial
Detailed data from the first Phase III trial of Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) lived up to expectations, boosting analyst confidence in the outcome of a second Phase III trial to be revealed Nov. 2. (BioWorld Today)